The role of PCSK9 in intestinal lipoprotein metabolism

Synergism of statin and ezetimibe

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Proprotein convertase subtilisin/kexin type 9 (PCSK9) plays a major role in the regulation of lipoprotein metabolism, mostly through control of low-density lipoprotein receptor degradation. Depletion of cellular cholesterol causes a compensatory increase in plasma PCSK9 levels, which can diminish the cholesterol-lowering power of statins and may lead to the overproduction of intestinal lipoproteins, mainly thorough the up regulation of microsomal triglyceride transfer protein and the Niemann-Pick C1-like 1 protein, the target of ezetimibe. Thus, ezetimibe therapy may counter this unwanted effect of statins, providing an additional theoretical rationale for combining the effect of ezetimibe on intestinal cholesterol absorption and that of statins on cholesterol synthesis.

Original languageEnglish (US)
Pages (from-to)23-26
Number of pages4
JournalAtherosclerosis Supplements
Volume17
DOIs
StatePublished - Feb 1 2015
Externally publishedYes

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Lipoproteins
Cholesterol
LDL Receptors
Intestinal Absorption
Up-Regulation
Proprotein Convertase 9
Ezetimibe
Proteins
Therapeutics

Keywords

  • Ezetimibe
  • LDL receptor

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Internal Medicine
  • Medicine(all)

Cite this

The role of PCSK9 in intestinal lipoprotein metabolism : Synergism of statin and ezetimibe. / Fazio, Sergio.

In: Atherosclerosis Supplements, Vol. 17, 01.02.2015, p. 23-26.

Research output: Contribution to journalArticle

@article{12cc4f96b638487aabaa491652552cc0,
title = "The role of PCSK9 in intestinal lipoprotein metabolism: Synergism of statin and ezetimibe",
abstract = "Proprotein convertase subtilisin/kexin type 9 (PCSK9) plays a major role in the regulation of lipoprotein metabolism, mostly through control of low-density lipoprotein receptor degradation. Depletion of cellular cholesterol causes a compensatory increase in plasma PCSK9 levels, which can diminish the cholesterol-lowering power of statins and may lead to the overproduction of intestinal lipoproteins, mainly thorough the up regulation of microsomal triglyceride transfer protein and the Niemann-Pick C1-like 1 protein, the target of ezetimibe. Thus, ezetimibe therapy may counter this unwanted effect of statins, providing an additional theoretical rationale for combining the effect of ezetimibe on intestinal cholesterol absorption and that of statins on cholesterol synthesis.",
keywords = "Ezetimibe, LDL receptor",
author = "Sergio Fazio",
year = "2015",
month = "2",
day = "1",
doi = "10.1016/S1567-5688(15)50006-8",
language = "English (US)",
volume = "17",
pages = "23--26",
journal = "Atherosclerosis Supplements",
issn = "1567-5688",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - The role of PCSK9 in intestinal lipoprotein metabolism

T2 - Synergism of statin and ezetimibe

AU - Fazio, Sergio

PY - 2015/2/1

Y1 - 2015/2/1

N2 - Proprotein convertase subtilisin/kexin type 9 (PCSK9) plays a major role in the regulation of lipoprotein metabolism, mostly through control of low-density lipoprotein receptor degradation. Depletion of cellular cholesterol causes a compensatory increase in plasma PCSK9 levels, which can diminish the cholesterol-lowering power of statins and may lead to the overproduction of intestinal lipoproteins, mainly thorough the up regulation of microsomal triglyceride transfer protein and the Niemann-Pick C1-like 1 protein, the target of ezetimibe. Thus, ezetimibe therapy may counter this unwanted effect of statins, providing an additional theoretical rationale for combining the effect of ezetimibe on intestinal cholesterol absorption and that of statins on cholesterol synthesis.

AB - Proprotein convertase subtilisin/kexin type 9 (PCSK9) plays a major role in the regulation of lipoprotein metabolism, mostly through control of low-density lipoprotein receptor degradation. Depletion of cellular cholesterol causes a compensatory increase in plasma PCSK9 levels, which can diminish the cholesterol-lowering power of statins and may lead to the overproduction of intestinal lipoproteins, mainly thorough the up regulation of microsomal triglyceride transfer protein and the Niemann-Pick C1-like 1 protein, the target of ezetimibe. Thus, ezetimibe therapy may counter this unwanted effect of statins, providing an additional theoretical rationale for combining the effect of ezetimibe on intestinal cholesterol absorption and that of statins on cholesterol synthesis.

KW - Ezetimibe

KW - LDL receptor

UR - http://www.scopus.com/inward/record.url?scp=84924943883&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84924943883&partnerID=8YFLogxK

U2 - 10.1016/S1567-5688(15)50006-8

DO - 10.1016/S1567-5688(15)50006-8

M3 - Article

VL - 17

SP - 23

EP - 26

JO - Atherosclerosis Supplements

JF - Atherosclerosis Supplements

SN - 1567-5688

ER -